{"id":14683,"date":"2024-01-14T08:49:09","date_gmt":"2024-01-14T08:49:09","guid":{"rendered":"https:\/\/v4.fadingstar.mx\/?p=14683"},"modified":"2024-01-15T19:25:41","modified_gmt":"2024-01-15T19:25:41","slug":"ill-save-you-some-tedious-reading","status":"publish","type":"post","link":"https:\/\/v4.fadingstar.mx\/2024\/01\/14\/ill-save-you-some-tedious-reading\/","title":{"rendered":"I’ll save you some tedious reading"},"content":{"rendered":"\n
HIV is<\/span> mRNA<\/strong> – or rather, it is an aberrant DNA checkpoint\/repair process where a specific<\/strong> dinucleotide substitution for glutamic acid presents as “GAG.” <\/p>\n\n\n\n GAA is the normal dinucleotide for glutamic acid – observed in the same DNA checkpoint\/repair process – in people who are not considered to have “HIV.” <\/p>\n\n\n\n GAA is “normal” in as much as it has a 3:1 prevalence over GAG.<\/p>\n\n\n\n GAA is among the twenty four most abundantly used codons in “covid.”<\/p>\n\n\n\n In the same sense that GAG was an “abundantly used” mRNA codon in “HIV.” <\/p>\n\n\n\n I believe that this dinucleotide substitution is an unrecognized manifestation of G6PD expression rather than one of “HIV.”<\/p>\n\n\n\n Kanamycin, neomycin, and\/or “etfak” knock out NEF in the “stop codon” of “hiv” with as much efficacy as a protease inhibitor due to ribosomal frameshifting but they’re going to need to acknowledge that it’s mRNA first.<\/p>\n\n\n\n (It is.)<\/p>\n\n\n\n Protease inhibitors – used in “covid” and “hiv” – only even work<\/strong> in the first place<\/strong> because of ribosomal frameshifting<\/strong>.<\/p>\n\n\n\n Ribosomes maintain the reading frame of an mRNA sequence being translated.<\/em> <\/p>\n\n\n\n Protease inhibitors “work” in an ORF where 99\/100 copies are so defective that they are already<\/strong> replication-incompetent with or without protease inhibitors.<\/p>\n\n\n\n Kanamycin, neomycin, and “etfak” cause ribosomal frameshifting in NEF: These are active in the stop codon against 1\/100 that are even replication competent.<\/p>\n\n\n\n Darpa and Moderna\u2019s early 2019 trials had already been underway since 2017 under Defense Advanced Research Projects Agency grant HR0011-17-2-0069<\/strong> and Gates Foundation grant OPP1066832.<\/strong><\/p>\n\n\n\n These were originally paid out in the pursuit of an \u201chiv\u2019 vaccine and\/or for DARPA\u2019s P3 Pandemic \u201cPrevention\u201d program starting in 2017.<\/p>\n\n\n\n